ERBB2 and neoplasm: Analogous to the lack of ALM targeting seen against MDA-MB-468 (ErbB2‘−’/ErbB3‘+’) xenografts, 125I-ALD, which has a functional anti-ErbB3 arm but no ability to bind to ErbB2, only accumulated to 0.55±0.16% ID per g in SK-OV-3 (ErbB2‘+’/ErbB3‘+’) tumours, a level that did not differ from that seen in blood (P=0.78, Figure 4B).